Press Releases on November 12, 2020 - EIN Presswire - Press Release Distribution Service

Published on November 12, 2020 - 21:05 GMT

IMPORTANT NOV. 20 DEADLINE Pawar Law Group Announces a Securities Class Action Lawsuit Against GoHealth, Inc. – GOCO

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of GoHealth, Inc. (NASDAQ: GOCO) pursuant and/or traceable to the registration statement issued …

Distribution channels: Consumer Goods, Law ...

Published on November 12, 2020 - 21:04 GMT

Angler Spotlight: Neil Lamm Caught a Close-to-Home Trout Slam

By Molly Kirk Photos by Courtesy of Neil Lamm Each month in the Fishing Notes from the Field email, we at the Department of Wildlife Resources (DWR) are going to highlight one of our constituents and the role fishing plays in their life. Are you an avid …

Distribution channels:

Published on November 12, 2020 - 21:05 GMT

Motus GI Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Revenue growth reflects rebound of inpatient colonoscopy volumes in Q3 and increased demand for the Pure-Vu system from early adopter hospitals Q3 Pure-Vu-enabled procedures increased by more than 50% above prior quarterly average First major metropolitan …

Distribution channels:

Published on November 12, 2020 - 21:05 GMT

Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates

Early Interim Data for TRIDENT-1 Phase 2 Study of Repotrectinib and Second Drug Candidate, TPX-0022, Recently Presented Phase 2 TRIDENT-1 Registrational Study Full Site Activation and Timeline Update Anticipated in Early 2021 Four Clinical Studies of Three …

Distribution channels:

Published on November 12, 2020 - 21:05 GMT

Relay Therapeutics Reports Third Quarter 2020 Financial Results

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today reported third …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on November 12, 2020 - 21:05 GMT

Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update

SANTA MONICA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three …

Distribution channels:

Published on November 12, 2020 - 21:05 GMT

C4 Therapeutics Reports Business Highlights and Third Quarter 2020 Financial Results

– Strengthened leadership team with appointments of Andrew Hirsch as Chief Executive Officer, William McKee as Chief Financial Officer and Jolie M. Siegel as Chief Legal Officer – – Completed upsized IPO in October 2020, raising $209.8 million in gross …

Distribution channels: Business & Economy, Technology ...

Published on November 12, 2020 - 21:05 GMT

ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights

BURLINGAME, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the …

Distribution channels:

Published on November 12, 2020 - 21:05 GMT

NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results

NGM continues to demonstrate the productivity of its research discovery engine and progress against its multi-therapeutic area pipeline: -- Initiated a Phase 2 clinical trial of NGM621, an anti-complement C3 antibody, in patients with geographic …

Distribution channels:

Published on November 12, 2020 - 21:05 GMT

Onconova Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

ON 123300, our proprietary multi-kinase inhibitor, enters into the clinic for advanced solid tumors Investigator-initiated study advances with combination of oral rigosertib and nivolumab in K-RAS mutated non-small cell lung cancer Actively evaluating …

Distribution channels:

Published on November 12, 2020 - 21:05 GMT

SIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020

NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Dennis Hruby, Chief Scientific Officer, will participate in …

Distribution channels: Culture, Society & Lifestyle, Technology ...

Published on November 12, 2020 - 21:05 GMT

ATA Creativity Global Reports 2020 Third Quarter Financial Results

BEIJING, China, Nov. 12, 2020 (GLOBE NEWSWIRE) -- ATA Creativity Global (“ACG” or the “Company”, Nasdaq: AACG), an international educational services company focused on providing quality learning experiences that cultivate and enhance students’ creativity, …

Distribution channels:

Published on November 12, 2020 - 21:05 GMT

Dynagas LNG Partners LP Reports Results for the Three and Nine Months Ended September 30, 2020

ATHENS, Greece, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Dynagas LNG Partners LP (NYSE: “DLNG”) (“Dynagas Partners” or the “Partnership”), an owner and operator of liquefied natural gas (“LNG”) carriers, today announced its results for the three and nine months …

Distribution channels: Business & Economy, Culture, Society & Lifestyle ...

Published on November 12, 2020 - 21:05 GMT

Eton Pharmaceuticals Announces Third Quarter 2020 Financial Results

DEER PARK, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today reported financial results …

Distribution channels:

Published on November 12, 2020 - 21:05 GMT

Agile Therapeutics Reports Third Quarter 2020 Financial Results

Commercial Launch of Twirla® Expected by Year-End 2020 $71.9 Million in Cash, Cash Equivalents, and Marketable Securities as of September 30, 2020 Management to Host Conference Call today at 4:30 PM ET PRINCETON, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on November 12, 2020 - 21:05 GMT

Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease ...

– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...

Published on November 12, 2020 - 21:05 GMT

Athira Pharma Reports Third Quarter 2020 Financial Results and Provides Business Highlights

- LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer’s disease, actively enrolling - Strong cash, cash equivalents and investments balance of $259.9 million as of September 30, …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on November 12, 2020 - 21:05 GMT

Xcel Brands, Inc. Announces Third Quarter 2020 Results

Third quarter total revenues of $7.4 million rebounding 46% from the second quarter Continued expense reduction actions; third quarter operating costs decreased more than $1 million year-over-year and product sale margins improved by 6% GAAP net loss of $0 …

Distribution channels: Business & Economy, Retail ...

Published on November 12, 2020 - 21:05 GMT

aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update

Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data is expected at turn of calendar year. Announces Investigational New Drug candidate in oncology, ATYR2810, from its NRP2 antibody …

Distribution channels:

Published on November 12, 2020 - 21:05 GMT

Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual London Healthcare Conference

WEST CHESTER, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, …

Distribution channels: